For the good of the patient: risks and benefits of medicines

被引：8

作者：

Breckenridge, A ^{[1
]}

机构：

[1] Univ Liverpool, Dept Pharm & Therapeut, Liverpool L69 3BX, Merseyside, England

来源：

PHARMACOEPIDEMIOLOGY AND DRUG SAFETY | 2003年 / 12卷 / 02期

关键词：

medicines; risks; benefits; pharmacovigilance;

D O I：

10.1002/pds.805

中图分类号：

R1 [预防医学、卫生学];

学科分类号：

1004 ; 120402 ;

摘要：

The basis of regulation of medicines is an assessment of risk and benefit. As the process of drug development has evolved with the advances in scientific knowledge, new and more precise methods of measuring drug efficacy have been created. Pharmacovigilance must also change with as much emphasis being placed on demonstrating the safety of a medicine as on preventing harm. Communication of these issues to interested parties remains problematical with room for considerable improvement. Copyright (C) 2003 John Wiley Sons, Ltd.

引用

页码：145 / 150

页数：6

共 10 条

[1] Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment [J].

Drazen, JM ;

Yandava, CN ;

Dubé, L ;

Szczerback, N ;

Hippensteel, R ;

Pillari, A ;

Israel, E ;

Schork, N ;

Silverman, ES ;

Katz, DA ;

Drajesk, J .

NATURE GENETICS, 1999, 22 (02) :168-170

[2] Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the philadelphia chromosome. [J].

Druker, BJ ;

Sawyers, CL ;

Kantarjian, H ;

Resta, DJ ;

Reese, SF ;

Ford, JM ;

Capdeville, R ;

Talpaz, M .

NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (14) :1038-1042

[3] Genetic variations in HLA-B region and hypersensitivity reactions to abacavir [J].

Hetherington, S ;

Hughes, AR ;

Mosteller, M ;

Shortino, D ;

Baker, KL ;

Spreen, W ;

Lai, E ;

Davies, K ;

Handley, A ;

Dow, DJ ;

Fling, ME ;

Stocum, M ;

Bowman, C ;

Thurmond, LM ;

Roses, AD .

LANCET, 2002, 359 (9312) :1121-1122

[4] Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir [J].

Mallal, S ;

Nolan, D ;

Witt, C ;

Masel, G ;

Martin, AM ;

Moore, C ;

Sayer, D ;

Castley, A ;

Mamotte, C ;

Maxwell, D ;

James, I ;

Christiansen, FT .

LANCET, 2002, 359 (9308) :727-732

[5]

Reid J J, 2001, Curr Opin Investig Drugs, V2, P68

[6] Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. [J].

Slamon, DJ ;

Leyland-Jones, B ;

Shak, S ;

Fuchs, H ;

Paton, V ;

Bajamonde, A ;

Fleming, T ;

Eiermann, W ;

Wolter, J ;

Pegram, M ;

Baselga, J ;

Norton, L .

NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (11) :783-792

[7]

Sykes R, 2000, NEW MED PRACTICE MED

[8]

WALLER P, 2002, IN PRESS PHARMACOEPI

[9]

Waller PC, 1999, PHARMACOEPIDEM DR S, V8, P535, DOI 10.1002/(SICI)1099-1557(199912)8:7<535::AID-PDS456>3.0.CO

[10]

2-D

← 1 →